> top > docs > PMC:7241115 > divs

PMC:7241115 JSONTXT

Divisions (16) JSON TSV

div. section text # proj. size # Ann.
0 TIAB Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hosp 3 1885 26 show
1 Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused substantial morbidity and mo 3 1501 21 show
2 METHODS Participants and data collection This retrospective study included all patients who were admitted to 3 2348 23 show
3 METHODS Virologic investigations Laboratory identification of SARS-CoV-2 infection was made at Wuhan Jinyint 3 1043 8 show
4 METHODS LPV/r treatment LPV/r (400 mg and 100 mg, orally, twice daily) was administered to the laboratory-co 3 415 5 show
5 METHODS Statistical analysis Data were presented as median (interquartile range, IQR) for continuous variabl 3 1653 10 show
6 RESULTS Patient characteristics From 31 January 2020 to 9 March 2020, 168 confirmed cases were admitted to o 3 1332 17 show
7 RESULTS Duration of viral shedding and risk factors The median duration of SARS-CoV-2 RNA shedding was 23 da 3 1831 17 show
8 RESULTS The effect of Lopinavir/Ritonavir treatment Of the 120 patients, 78 patients (65%) were administered 3 1444 29 show
9 Discussion Viral shedding was commonly used as a proxy measure for the infectivity. Therefore, identification o 3 7402 112 show
10 Caption-FIGURE 1 Distribution of the number of patients with undetectable SARS-CoV-2 RNA by day after symptom onset. 3 99 2 show
11 Caption-FIGURE 2 Distribution of time to the initiation of Lopinavir/Ritonavir treatment from symptom onset. 3 91 1 show
12 Caption-FIGURE 3 The cumulative proportion of patients with detectable SARS-CoV-2 RNA over time. a) Cumulative propor 3 514 14 show
13 Caption-TABLE 1 Characteristics of 120 Hospitalised Patients with SARS-CoV-2 infection in Wuhan 3 79 2 show
14 Caption-TABLE 2 Multivariable Logistic Regression analysis of Factors associated with Duration of SARS-CoV-2 RNA Det 3 144 2 show
15 Caption-TABLE 3 Comparison of clinical features of patients with SARS-CoV-2 infection who treated with Lopinavir/Rit 3 147 4 show